Xeljanz and Joint swelling - a phase IV clinical study of FDA data
Summary:
Joint swelling is found among people who take Xeljanz, especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months.
The phase IV clinical study analyzes which people take Xeljanz and have Joint swelling. It is created by eHealthMe based on reports of 192,294 people who have side effects when taking Xeljanz from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
192,294 people reported to have side effects when taking Xeljanz.
Among them, 15,442 people (8.03%) have Joint swelling.
What is Xeljanz?
Xeljanz has active ingredients of tofacitinib citrate. It is often used in rheumatoid arthritis. eHealthMe is studying from 192,437 Xeljanz users for its effectiveness, alternative drugs and more.
What is Joint swelling?
Joint swelling is found to be associated with 3,286 drugs and 2,790 conditions by eHealthMe.
Number of Xeljanz and Joint swelling reports submitted per year:
Time on Xeljanz when people have Joint swelling *:
Gender of people who have Joint swelling when taking Xeljanz*:
Age of people who have Joint swelling when taking Xeljanz *:
Common drugs people take besides Xeljanz *:
Common side effects people have besides Joint swelling *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Xeljanz and have Joint swelling?
Check whether Joint swelling is associated with a drug or a conditionHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related studies
How severe was Joint swelling and when was it recovered:
Expand to all the drugs that have ingredients of tofacitinib citrate:
- Joint swelling and drugs with ingredients of tofacitinib citrate (15,670 reports)
Alternative drugs to, pros and cons of Xeljanz:
- Xeljanz (192,437 reports)
Common Xeljanz side effects:
- Drug ineffective: 48,562 reports
- Pain: 26,984 reports
- Joint pain: 21,086 reports
- Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints): 20,971 reports
- Fatigue (feeling of tiredness): 16,775 reports
- Joint swelling: 15,442 reports
- Headache (pain in head): 13,556 reports
- Rashes (redness): 12,562 reports
- Malaise (a feeling of general discomfort or uneasiness): 11,656 reports
Browse all side effects of Xeljanz:
a b c d e f g h i j k l m n o p q r s t u v w x y zJoint swelling treatments and more:
- Joint swelling (118,597 reports)
COVID vaccines that are related to Joint swelling:
- Joint swelling in Moderna COVID Vaccine
- Joint swelling in Pfizer BioNTech Covid Vaccine
- Joint swelling in Johnson and Johnson Covid Vaccine
Common drugs associated with Joint swelling:
- Methotrexate: 29,058 reports
- Enbrel: 29,056 reports
- Humira: 24,773 reports
- Prednisone: 19,690 reports
- Orencia: 17,226 reports
- Actemra: 15,891 reports
- Xeljanz: 15,442 reports
- Sulfasalazine: 13,386 reports
- Leflunomide: 12,445 reports
- Arava: 12,313 reports
All the drugs that are associated with Joint swelling:
- Joint swelling (3,286 drugs)
Common conditions associated with Joint swelling:
- Rheumatoid arthritis: 43,452 reports
- High blood pressure: 5,596 reports
- Pain: 4,638 reports
- Psoriasis: 4,042 reports
- Osteoporosis: 2,823 reports
- High blood cholesterol: 2,815 reports
- Multiple myeloma: 2,665 reports
All the conditions that are associated with Joint swelling:
- Joint swelling (2,790 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on tofacitinib citrate (the active ingredients of Xeljanz) and Xeljanz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Megace and Weakness - 4 seconds ago
- Slynd and Rashes - 20 seconds ago
- Pramine and Atrial Fibrillation Aggravated - 26 seconds ago
- Benicar Hct and Angioplasty - 38 seconds ago
- Nicoderm Cq and Hypoaesthesia Oral - 46 seconds ago
- Diazepam and Skin Fragility - 49 seconds ago
- Sinemet and Infarction - a minute ago
- Levothyroxine Sodium and Venous Insufficiency - a minute ago
- Trospium Chloride and Coronary Artery Stenosis - a minute ago
- Levonorgestrel and Pulmonary Embolism - a minute ago